Anacetrapib
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2]
Other CETP inhibitors:
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2]
Other CETP inhibitors: